Connor Clark & Lunn Investment Management Ltd. Lowers Position in XBiotech Inc. $XBIT

Connor Clark & Lunn Investment Management Ltd. lessened its stake in XBiotech Inc. (NASDAQ:XBIT) by 12.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,185 shares of the biopharmaceutical company’s stock after selling 9,009 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.21% of XBiotech worth $211,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of XBiotech by 68.2% during the 4th quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company’s stock valued at $58,000 after buying an additional 5,930 shares in the last quarter. Bank of America Corp DE lifted its position in shares of XBiotech by 42.0% during the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company’s stock valued at $79,000 after buying an additional 5,887 shares in the last quarter. Barclays PLC lifted its position in shares of XBiotech by 13.9% during the 4th quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 3,661 shares in the last quarter. Deutsche Bank AG purchased a new position in shares of XBiotech during the 4th quarter valued at approximately $120,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of XBiotech by 15.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 8,918 shares in the last quarter. Hedge funds and other institutional investors own 55.70% of the company’s stock.

XBiotech Price Performance

Shares of NASDAQ:XBIT opened at $3.22 on Thursday. XBiotech Inc. has a 1 year low of $2.50 and a 1 year high of $8.32. The firm has a market capitalization of $98.18 million, a price-to-earnings ratio of -3.50 and a beta of 0.97. The business’s 50 day moving average price is $2.92 and its 200-day moving average price is $3.03.

XBiotech (NASDAQ:XBIT) last announced its earnings results on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.